Malta - English - Medicines Authority

macleods pharma uk ltd wynyard park house, wynyard avenue, wynyard, billingham ts22 5tb , united kingdom - carbimazole - tablet - carbimazole 10 mg - thyroid therapy

Malta - English - Medicines Authority

macleods pharma uk ltd wynyard park house, wynyard avenue, wynyard, billingham ts22 5tb , united kingdom - propylthiouracil - tablet - propylthiouracil 50 mg - thyroid therapy

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - bleomycin sulfate - powder for solution for injection - 15000unit

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - bleomycin sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 100 mg - capsule - excipient ingredients: iron oxide red; gelatin; purified water; glycerol; sodium propyl hydroxybenzoate; citric acid; sodium ethyl hydroxybenzoate; titanium dioxide; macrogol 400 - 1 - small cell carcinoma of the lung 2 - acutre monocytic and myelomoncytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphoma indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 50 mg - capsule - excipient ingredients: sodium propyl hydroxybenzoate; glycerol; sodium ethyl hydroxybenzoate; citric acid; iron oxide red; gelatin; titanium dioxide; macrogol 400; purified water - 1 - small cell carcinoma of the lung 2 - acute monocytic and myelomonocytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphonia indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. metformin hydrochloride tablets are contraindicated in patients with: • severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ).  • known hypersensitivity to metformin hydrochloride. • acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. ibandronate sodium tablets increases bone mineral density (bmd) and reduce the incidence of vertebral fractures. the optimal duration of use has not been determined. the safety and effectiveness of ibandronate sodium tablets for the treatment of osteoporosis are based on clinical data of three years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. ibandronate sodium tablets are contraindicated in patients with the following conditions:   o abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see warnings and precautions [5.1] )   o inability to stand or sit upright for at le

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 15 days and older [see clinical studies (14.1, 14.2)]. limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine tablets  is not recommended to be initiated, unless the  benefit outweighs the risk, in: • adult females with cd4+ cell counts greater than 250 cells/mm3 or • adult males with cd4+ cell counts greater than 400 cells/mm3 [see warnings and precautions (5.1)]. nevirapine  is contraindicated: • in patients with moderate or severe (child-pugh class b or c, respectively) hepatic impairment [see warnings and precautions (5.1) and use in specific populations (8.7)]. • for use as part of occupational and non-occupational post-exposure prophylaxis (pep) regimens [see warnings and precautions (5.1)]. pregnancy exposure registry